McKesson Corporation (MCK)
| Market Cap | 51.56B |
| Revenue (ttm) | 273.90B |
| Net Income (ttm) | 3.14B |
| Shares Out | 141.79M |
| EPS (ttm) | 21.78 |
| PE Ratio | 16.69 |
| Forward PE | 14.25 |
| Dividend | $2.02 (0.56%) |
| Ex-Dividend Date | Nov 30, 2022 |
| Volume | 843,016 |
| Open | 357.70 |
| Previous Close | 358.13 |
| Day's Range | 355.73 - 364.54 |
| 52-Week Range | 260.73 - 401.78 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 430.88 (+18.5%) |
| Earnings Date | Feb 1, 2023 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialt... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for MCK stock is "Buy." The 12-month stock price forecast is $430.88, which is an increase of 18.50% from the latest price.
News
Here's Why McKesson (MCK) is Poised for a Turnaround After Losing -6.24% in 4 Weeks
The heavy selling pressure might have exhausted for McKesson (MCK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in...
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes"
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
5 Dental Supplies Stocks to Buy Amid Recovering Prospects
Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.
McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up
McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.
McKesson (MCK) Tops Q3 Earnings and Revenue Estimates
McKesson (MCK) delivered earnings and revenue surprises of 8.83% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
McKesson Corporation Reports Fiscal 2023 Third-Quarter Results
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2023 third-quarter financial results. Results can be accessed on McKesson's Investor Relations website at inv...
Are Medical Stocks Lagging McKesson (MCK) This Year?
Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services...
2 Medical Stocks to Consider Buying Before Earnings
There is a continued need for prosperous healthcare companies, here are two medical stocks investors may want to consider buying ahead of earnings this week.
McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on...
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson Receives Approval of Its Near-term Climate Change Targets by the Globally Recognized Science Based Targets initiative
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term climate change targets th...
4 Stocks Trading Near 52-Week High That Can Scale Higher
Investors target stocks that have been on a bullish run lately. Stocks like HRI, DCP, MRC and MCK that are seeing price strength have a high chance of carrying the momentum forward.
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
Here is how McKesson (MCK) and Doctor Reddy's (RDY) have performed compared to their sector so far this year.
These were Warren Buffett's 10 best performing stocks held by Berkshire Hathaway in 2022
Some of the best performers have been owned by Buffett for decades, like Coca-Cola, while others are new additions to the portfolio, like T-Mobile.
McKesson (MCK) Flat As Market Sinks: What You Should Know
In the latest trading session, McKesson (MCK) closed at $375.12, marking no change from the previous day.
Are Investors Undervaluing McKesson (MCK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
3 Stocks to Sell Ahead of a Recession in 2023
If you are an investor looking for stocks to sell before a recession next year, you'll most likely be hitting the mark. While 2022 has been an alarming year for stocks due to rampant inflation and rat...
McKesson Corporation Announces Third-Quarter Fiscal 2023 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third-quarter fiscal 2023 financial results after market close on Wednesday, February 1, 2023. The company will host...
Here's Why You Should Retain McKesson (MCK) Stock Right Now
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
McKesson (MCK) Announces Availability of FDA-Accepted Drug
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.
McKesson (MCK) Announces Availability of FDA-Approved Drug
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.